Measles Rubella Cipla
Powder and diluent for solution for Injection 0 5 mL 5 mL
registration number
55/30.2/0426
What Measles Rubella Cipla is and what it is used for
Measles Rubella Cipla is indicated for:
• active immunisation against measles and rubella in infants and children from the age of 9 months and older, adolescents and young adults at risk
• immunisation of susceptible non-pregnant adolescent and adult females of childbearing age is indicated if certain precautions are observed.
dosage
Measles virus1 (Edmonston Zagreb strain) (live attenuated): not less than 1000 CCID502
Rubella virus1 (Wistar RA 27/3 strain) (live attenuated): not less than 1000 CCID502.
how to take
You will not be expected to give yourself Measles Rubella Cipla injection.
It will be given to you by a person who is qualified to do so. Measles Rubella Cipla should be injected into the fatty tissues just beneath the skin either in the area of the outer thigh in infants or upper arm in older children and adults.
Measles Rubella Cipla is given as follows
The dose of the vaccine is the same for everyone, being 0,5 mL of the reconstituted vaccine.
If your child gets the vaccination when he or she is less than one year old, a second dose should be given when they are 15 to 18 months old. If your child gets the vaccination when he or she is one year or older, a second
dose is recommended. Often the second dose is given right before the child starts school (4 to 6 years of age).
Non-pregnant adolescent and adult females of childbearing age who are susceptible to rubella can be vaccinated with Measles Rubella Cipla (or a live weakened rubella virus vaccine) if certain precautions are taken.
What Measles Rubella Cipla contains
Measles virus1 (Edmonston Zagreb strain) (live attenuated)
Rubella virus1 (Wistar RA 27/3 strain) (live attenuated).
other ingredients
Powder:
Partially hydrolysed Gelatine, Sorbitol, L-Histidine, L-Alanine, Tricine, L-Arginine Hydrochloride,
Lactalbumin Hydrolysate, Minimum Essential Medium.
Diluent:
Sterile Water for injection.
Therapeutic classification
J07BD53.